What's new

Opinion/decision on a Paediatric investigation plan (PIP): Steglatro, Ertugliflozin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: P/0189/2024

Opinion/decision on a Paediatric investigation plan (PIP): Steglatro, Ertugliflozin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: P/0189/2024

Jun 25, 2025 - 11:10
 0
Opinion/decision on a Paediatric investigation plan (PIP): Steglatro, Ertugliflozin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: P/0189/2024
Opinion/decision on a Paediatric investigation plan (PIP): Steglatro, Ertugliflozin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: P/0189/2024
Read More

Tags:

Previous Article

EMEA-002489-PIP02-24

Next Article

EMEA-000534-PIP03-17-M01

Related Posts

Human medicines European public assessment report (EPAR): Absimky, ustekinumab, Date of authorisation: 12/12/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025  0

Human medicines European public assessment report (EPAR): Cyramza, ramucirumab, Date of authorisation: 19/12/2014, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 18, 2025  0

EMA/FVE info session for veterinary practitioners : Understanding the first report of sales and use of antimicrobials in animals, Online, European Medicines Agency, Amsterdam, the Netherlands, from 3 June 2024, 15:30 (CEST) to 3 June 2024, 16:30 (CEST)

EMA/FVE info session for veterinary practitioners : Und...

May 12, 2025  0